HIV Clinical Pharmacology & Therapeutics Research Training Program

这是 D43 的续签申请，标题为 HIV 临床药理学和治疗研究培训 (HIVRT) 项目由布法罗大学 (UB) 和津巴布韦大学 (UZ) 领导。优化艾滋病毒 通过 HIV PReP 和治疗作为预防 (TasP) 来预防传播，以满足 95-95-95 和“结束 疫情”策略。然而，成功使用这些方法需要继续研究 旨在指导中低收入国家的实施。 HIVRT 将增加 合格的研究人员为这项研究工作寻求外部资金。随着替诺福韦的推出， 拉米夫定和多替拉韦、长效抗逆转录病毒药物（例如卡博特韦、利匹韦林）、新型抗逆转录病毒药物（例如来那卡韦、 islatravir）和 HIV-1 广泛中和抗体（bNAB），与这些相关的临床和转化研究 需要新的治疗药物来检查最佳药代动力学-药效学参数 将防止传播和/或维持病毒载量抑制以及合并症情况下的安全性。 临床医生科学家和转化科学家的培训将利用先前建立的基础 UB-UZ HIVRT 和过渡到新设计的研究培训计划。具体目标：1) 提供 HIVRT 对于博士前 (5) 和博士后 (5) 实习生来说，增加了具有独立、 资助的项目重点关注艾滋病毒临床药理学和治疗以及区域公共卫生优先事项 包括 COVID-19，2) 在团队科学方面指导 HIVRT 受训者，其中包括其他具有以下专业知识的人 药物生物分析、生物医学信息学、数据科学、基因组学和微生物组，3) Foster 社区支持小组参与创新研究，研究新型艾滋病毒临床 预防和治疗的药理学和治疗策略并研究长效 抗逆转录病毒药物、单克隆抗体和传统药物，以及 4) 提供 HIVRT 来培养聪明的 旨在实现可持续发展目标的学术-公私伙伴关系。学员将拥有 布法罗大学的强化培训期间，新的知识和技能将有助于制定一个研究项目， 将在 UZ 持续监督下进行 18 个月，总共两年的培训。的 计划将建立在我们之前的福格蒂国际中心艾滋病毒研究培训计划和更早的 AITRP。这些研究培训计划为 D43 更新奠定了基础，其中包括 由 UZ 和 UB 导师组成的优秀团队将利用 HIV 临床提供指导和合作 为艾滋病毒临床和转化研究而建立的药理学和治疗学基础。的 课程将通过已建立的研究和教育培训核心来组织和提供。的 D43 拥有出色的外部培训咨询委员会，将有助于打造高效、高效的团队 津巴布韦的艾滋病毒临床药理学和治疗研究培训计划。

This is a renewal application for a D43 titled, HIV Clinical Pharmacology and Therapeutics Research Training (HIVRT) program led by the University at Buffalo (UB) and the University of Zimbabwe (UZ). Optimizing HIV prevention of transmission with HIV PReP and treatment as prevention (TasP) to meet 95-95-95 and “ending the epidemic” strategies. However, successful use of these approaches requires that continued research be conducted to guide implementation in low-middle income countries. The HIVRT will increase the number of qualified investigators to seek external funding for this research effort. With the introduction of tenofovir, lamivudine and dolutegravir, long-acting ARVs (e.g., cabotegravir, rilpivirine), new ARVs (e.g., lenacapavir, islatravir) and HIV-1 broadly neutralizing antibodies (bNABs), clinical and translational research related to these new therapeutic agents is needed to examine the optimal pharmacokinetics-pharmacodynamics parameters that will prevent transmission and/or sustain viral load suppression as well as safety in the context of co-morbidities. Training of clinician-scientists and translational scientists will utilize the foundation that has been built by the prior UB-UZ HIVRT and transition to the newly designed research training program. Specific Aims: 1) Provide a HIVRT for pre-doctoral (5) and post-doctoral (5) trainees that increases the number of researchers with independent, funded programs with a focus on HIV clinical pharmacology and therapeutics and regional public health priorities including COVID-19, 2) Mentor HIVRT trainees in team science and that include others with expertise in pharmaceutical bioanalysis, biomedical informatics, data sciences, genomics, and microbiome, 3) Foster community support group engagement to participate in innovative research to study novel HIV clinical pharmacology and therapeutics strategies for prevention and treatment and investigate long-acting antiretrovirals and monoclonal antibodies and traditional medicines, and 4) Provide an HIVRT that fosters smart academic-public-private partnerships aimed at addressing sustainable developmental goals. Trainees will have intensive training at UB during which new knowledge and skills will allow formulation of a research project that will be conducted under continued supervision for 18 months at UZ for a total of two years of training. The program will build on our prior Fogarty International Center HIV Research Training program, and an earlier AITRP. These research training programs provide the foundation for this D43 renewal that includes an outstanding group of UZ and UB mentors who will provide mentoring and collaboration utilizing the HIV Clinical Pharmacology and Therapeutics foundation that has been built for HIV clinical and translational research. The curriculum will be organized and provided through an established Research and Education Training Core. The D43 has an outstanding external Training Advisory Committee that will contribute to a highly productive, efficient HIV Clinical Pharmacology and Therapeutics research training initiative in Zimbabwe.